<DOC>
	<DOCNO>NCT00145418</DOCNO>
	<brief_summary>It accept proven patient unresectable lung cancer benefit systemic chemotherapy . Traditional platinum-based therapy significant side effect . Oxaliplatin docetaxel show effective lung cancer . The purpose study determine oxaliplatin combine docetaxel low toxicity profile determine response rate study drug combination .</brief_summary>
	<brief_title>Oxaliplatin Docetaxel First-line Therapy Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This study Phase II study design evaluate toxicity profile oxaliplatin docetaxel determine response rate study drug combination . The primary objective study response rate RECIST criterion . The secondary objective time progression , duration response , toxicity . Patients receive : - oxaliplatin 85mg/m2 2 hour Days 1 15 - docetaxel 30mg/m2 Days 1 8 Cycles repeat every 28 day maximum 6 cycle .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically confirm nonsmallcell lung cancer ( NSCLC ) Patients must measurable disease Age great equal 18 year ECOG performance score 0 , 1 , 2 Absolute neutrophil count ( ANC ) &gt; 1,500 Platelets &gt; 100,000 Serum creatinine &lt; 1.5mg/dL Serum total bilirubin &lt; 1.5mg/dL Alkaline phosphatase &lt; 3 time upper limit normal SGOT/SGPT &lt; 3 time upper limit normal Patients must recover effect prior surgery RT . Patients legal representative must able read , understand provide inform consent participate trial . Patients childbearing potential partner must agree use effective form contraception study 90 day follow last dose study medication . Patients active infection &gt; 38.5 degree Celsius within 3 day first schedule day protocol treatment Patients active central nervous system ( CNS ) metastasis . Patients stable CNS disease , undergone radiotherapy least 4 week prior plan first protocol treatment stable dose corticosteroid 2 week eligible trial . History prior malignancy within past 5 year except curatively treat basal cell carcinoma skin ; cervical intraepithelial neoplasm , localized prostate cancer current prostate specific antigen ( PSA ) &lt; 1.0 mg/dL Patients know hypersensitivity component oxaliplatin docetaxel Patients prior chemotherapy lung cancer Patients receive concurrent investigational therapy receive investigational therapy within 30 day first schedule day protocol treatment Grade 2 peripheral neuropathy Patients pregnant lactate Any medical condition , include mental illness substance abuse deem investigator likely interfere patient ' ability sign inform consent , cooperate participate study , interfere interpretation result History allogeneic transplant Known HIV , hepatitis B C ( active , previously treat , )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Non small Cell Lung Cancer Stage IIIb IV</keyword>
</DOC>